ArticleJournal of Korean medical science2025
Valproic Acid Inhibits RhoA-Mediated Vascular Smooth Muscle Cell Contraction.
Article in Journal of Korean medical science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundVascular smooth muscle cells (VSMCs) play an important role in regulating vessel diameter and blood pressure. Dysregulation of VSMC contraction contributes to the development of coronary and post-subarachnoid hemorrhagic (SAH) vasospasms. We investigated the molecular mechanisms by which valproic acid (VPA) inhibits Ras homolog family member A (RhoA)-mediated VSMC contraction in rat VSMCs and isolated aortas.
methodsIn rat VSMCs, western blot analyses, quantitative real-time reverse transcription-polymerase chain reaction, ectopic expression of the constitutively active (CA)-RhoA gene or wild-type (WT)-histone deacetylase (HDAC) 5 gene, and inhibitor studies were performed. Active RhoA-GTP levels and Rho-associated protein kinase activity in VSMCs were also measured. We performed a phenylephrine (PE)-induced aortic contraction assay using isolated rat aortas, as well as post hoc analyses of an endothelium-dependent aortic relaxation assay using aortas from VPA-administered mice.
resultsVPA decreased the phosphorylation of the myosin light chain at Ser19 (p-MLC-Ser¹⁹) in a dose- and time-dependent manner. Interestingly, VPA significantly decreased RhoA mRNA and protein expression, as well as the active RhoA-GTP level. Furthermore, ectopic expression of CA-RhoA gene almost completely reversed VPA-inhibited p-MLC-Ser¹⁹. VPA markedly increased the acetylation levels of histone 3 (H3K9ac/K14ac). VPA and sodium butyrate but not valpromide significantly decreased the expression levels of both RhoA and p-MLC-Ser¹⁹ in VSMCs. However, this decrease was not reversed by overexpression of the WT-HDAC5 gene, indicating that HDAC5 was not responsible for this decrease. Consistent with the
conclusionThis study showed that VPA inhibits RhoA-mediated VSMC and vessel contraction by decreasing RhoA expression, which is mediated by the inhibitory action of VPA on HDACs. These results suggest that VPA may be useful in the treatment and prevention of spastic vascular diseases, including coronary and post-SAH vasospasms.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.